Heron Therapeutics Faces Nasdaq Delisting Risk as Share Price Falls Below $1 ThresholdTip Ranks·1 day ago, 01:00 AMHRTX-3.34%
HRTX: Q2 2026 net revenue grew 9% sequentially, but full-year guidance was withdrawn amid legal uncertaintyQuartr·1 day ago, 07:11 AMHRTX-3.34%
Heron Q2 FY26 net loss widens to $5.49 million; net sales rise 1.3% to $37.67 millionPUBT·1 day ago, 07:09 AMHRTX-3.34%
Heron Therapeutics amends Hercules Capital credit facility, cuts principal by $13.5 millionPUBT·1 day ago, 07:03 AMHRTX-3.34%HTGC-0.18%
Heron Therap | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 37.67 MEarnings Watch·1 day ago, 07:02 AMHRTX-3.34%
Heron Therapeutics (HRTX) Projected to Post Quarterly Earnings on MondayMarket Beat·Aug 3 at 09:56 AMHRTX-3.34%
Heron Therapeutics to report Q2 results, host conference call and webcastPUBT·Jul 27 at 07:31 AMHRTX-3.34%
Heron Therapeutics gets Nasdaq notice after shares trade below $1 bid price requirementPUBT·Jun 25 at 04:01 PMHRTX-3.34%
PRF Technologies reports expanded preclinical head-to-head data for PRF-110 vs Zynrelef in porcine pain modelPUBT·Jun 25 at 07:31 AMHRTX-3.34%PRFX+4.76%
Heron Shareholders Approve Directors, Incentive Plans, Tax MeasuresTip Ranks·Jun 16 at 02:17 PMHRTX-3.34%
